Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03183245 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
A Phase 3 study, sponsored by Humacyte.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT03183245 is a Phase 3 study that has completed, run by Humacyte. The registered enrollment target is 242 participants.
The verdict
NCT03183245, a Phase 3 study, has completed, sponsored by Humacyte.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
Interventions
- BIOLOGICAL Human Acellular Vessel (HAV)
- OTHER Hemodialysis
- PROCEDURE Arteriovenous fistula (AVF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2025-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03183245
The ClinicalTrials.gov registry entry for NCT03183245 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Humacyte, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Human Acellular Vessel (HAV) is the first listed.
NCT03183245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03183245 about?
NCT03183245 is a clinical study titled "Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis". The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
What is the current status of trial NCT03183245?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2017-09-29. Estimated completion is 2025-06-19.
What interventions are being tested in trial NCT03183245?
The interventions under investigation include: Human Acellular Vessel (HAV) (BIOLOGICAL), Hemodialysis (OTHER), Arteriovenous fistula (AVF) (PROCEDURE).
Who is sponsoring clinical trial NCT03183245?
This trial is sponsored by Humacyte, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.